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The “cell kill” paradigm associated
with maximum-tolerated dose (MTD)
chemotherapy has shown remarkable suc-
cess in many hematological malignancies,
but unfortunately has failed to demon-
strate sustained responses in majority of
common advanced solid tumors. This
failure can be attributable to heterogene-
ity of cancer cells within the tumor in
terms of the rate of cell proliferation,
genetic makeup, and micro-environmental
selection giving rise to development of
treatment resistance. In this context,
Gatenby’s hypothesis of controlling tumor
growth rather than eradicating it and treat-
ing it like a chronic disease may be more
meaningful (1). The use of metronomic
regimens alone or in combination with
other new targeted therapies after MTD
chemotherapy as maintenance treatment
for longer period may pave the way for
long-term cost-effective treatment.
METRONOMIC CHEMOTHERAPY
Metronomic chemotherapy (MC), a term
initially coined by Hanahan, is defined
as administration of chemotherapeutic
agents at relatively low, minimally toxic
doses, and with no prolonged drug-free
breaks (2). This concept originated by pio-
neer work done by Klement et al. and
Browder et al. showing that mice bearing
subcutaneous tumors could respond to fre-
quent repeated low doses of chemotherapy,
even when they displayed acquired drug
resistance to the same agents given in a
conventional way (3, 4).
Several mechanisms of action have since
been proposed for MC, the major being
the inhibition of angiogenesis by selective
inhibition of proliferation and/or induc-
tion of apoptosis of activated endothelial
cells, selective inhibition of endothelial cell
migration, increase in the expression level
of the endogenous angiogenesis inhibitor
thrombospondin-1, and sustained decrease
in levels and viability of bone marrow-
derived endothelial progenitor cells (5).
In addition, MC has immuno-modulatory
effect through Treg depletion, NK cell and
T cell activation, and promoting dendritic
cell activation (5, 6). Overall, these prop-
erties may lead to re-induction of tumor
dormancy. Therefore, MC can be regarded
as an intrinsically multi-targeted therapy
(5, 7).
The use of MC in the clinic practice has
been mainly limited to palliative purposes
in relapse/refractory diseases, with good
response rates and a favorable toxicity pro-
file. In a recent systemic review of 80 small
single arm and phase II studies of low-dose
MC in various tumor types including 3700
patients, Lien et al. showed mean response
rates of 26%, median progression-free sur-
vival (PFS) of 4.6 months, and mean dis-
ease control rates of 56%. Grade 3/4
adverse events were found to be rare (ane-
mia 8%, fatigue 13%) (8). Building on these
encouraging results, nine phase III trials are
currently registered at ClinicalTrials.gov in
various clinical settings including adjuvant
and maintenance.
MAINTENANCE TREATMENT: SCOPE IN
VARIOUS SOLID TUMORS
The U.S. National Cancer Institute’s
(NCI’s) medical dictionary defines
maintenance therapy as “type of treatment
that is given to prevent progression after it has
been controlled successfully with the initial
therapy.” It includes treatment with drugs,
vaccines, or antibodies with anticancer
properties and may be given for extended
period of time. Aims of treatment in many
advanced cancers are to prolong survival
and improve patient’s quality of life. An
effective maintenance therapy should seek
to achieve both of these goals with a good
patient tolerance, lack of cumulative toxic-
ities, and cost–effectiveness. In this context,
two treatment paradigms have emerged;
continuation maintenance where one com-
ponent of initial therapy is continued after
the induction treatment and switch main-
tenance in which a new and potentially
cross-resistant agent is introduced (9).
Maintenance therapy has been classi-
cally used for hematological malignancies
like acute lymphoblastic leukemia (ALL)
(10, 11) and low-grade non-Hodgkin’s
lymphoma (12, 13). Recently, there has
been a growing interest to explore the
role of maintenance in various advanced
solid tumors. Advanced non-small cell
lung cancer (NSCLC), metastatic colorec-
tal cancer (CRC), metastatic breast can-
cer, and ovarian cancer are few examples
where maintenance treatments with either
chemotherapy or targeted therapies have
shown promising results. In NSCLC, most
of the strategies of either continuation or
switch maintenance demonstrated a signif-
icant improvement in PFS except for peme-
trexed and erlotinib which also showed an
overall survival (OS) improvement (9). A
recent meta-analysis incorporating data of
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3736 patients from eight randomized con-
trolled trials on maintenance treatment in
advanced NSCLC altogether suggest, that
OS and PFS are clearly in favor of mainte-
nance therapy for both, switch and contin-
uation strategy (14). Similarly for metasta-
tic breast cancer, a meta-analysis including
2269 patients from 11 randomized trials
showed a clear benefit of longer dura-
tion of chemotherapy in terms of PFS
and OS (15). Several studies in metastatic
CRC have demonstrated improvement in
survival by continuing part of the induc-
tion chemotherapy and/or targeted agents
beyond six cycles (16–18). The role of
maintenance chemotherapy in ovarian car-
cinoma has been more controversial, differ-
ent large randomized trials showing vari-
able results (19, 20). Recent meta-analysis
of 1644 patients from eight trials showed
no benefit of maintenance chemother-
apy in ovarian carcinoma (21). However,
anti-angiogenic agents like bevacizumab
have shown promising activity when com-
bined with chemotherapy and continued
as maintenance (22). In a recent phase
II study, olaparib, an oral poly[adenosine
diphosphate (ADP)–ribose] polymerase
inhibitor has also shown benefit in terms of
PFS when used as a maintenance therapy in
platinum-sensitive relapse ovarian cancers
(23). Results of an international Intergroup
trial (AGO-OVAR16) presented at annual
conference of American Society of Clinical
Oncology (ASCO) in 2013 demonstrated a
PFS benefit of pazopanib maintenance in
advanced epithelial ovarian cancer (24).
ECONOMIC AND QUALITY OF LIFE
CONSIDERATIONS WITH
MAINTENANCE TREATMENT
Cost–effectiveness and quality of life
are two other major issues associated
with prolonged use of maintenance ther-
apy. The economic impact of mainte-
nance for advanced cancers has been
studied in numerous cost–effectiveness
analyses. For example, the incremental
cost–effectiveness ratio (ICER) per life-
year gained with maintenance peme-
trexed in advanced NSCLC was esti-
mated to be $205,597 (25). Similarly,
in ovarian cancer, economic evaluation
of maintenance paclitaxel and mainte-
nance bevacizumab demonstrated that
compared with carboplatin–paclitaxel for
six cycles, maintenance paclitaxel had an
ICER of $13,402 per quality-adjusted life-
year while addition of bevacizumab to
carboplatin–paclitaxel and then as main-
tenance monotherapy had an ICER of
$326,530 per quality-adjusted life-year
(26). In a systematic review, addition of
bevacizumab to chemotherapy in metasta-
tic CRC was also found not to be cost-
effective (27).
Tolerance and compliance of chronic
treatment are major concerns but second
line therapy on progression can also lead
to global deterioration of quality of life due
to disease-related symptoms which may in
turn compromise the feasibility of second
line treatment. To date, no clinical trial has
demonstrated a significant improvement in
quality of life with maintenance treatment
as compared to observation. However, sev-
eral studies have shown that global qual-
ity of life does not deteriorate, indicating
the favorable toxicity profile of prolonged
administration of single-agent cytotoxic or
biological agents (28, 29).
Looking at maintenance with patient’s
perspective suggests that majority will pre-
fer maintenance over observation alone. In
a pilot survey of 30 patients, Peeters et al.
showed that metastatic NSCLC patients in
general were in favor of maintenance and
accepted either an OS benefit of at least sev-
eral months, or better symptom control, in
exchange for mild-to-moderate side effects.
There was a slight preference for oral vs.
intravenous administration (30).
METRONOMICS AS MAINTENANCE
THERAPY
The concept of metronomic maintenance
is not new. The success of this approach
in ALL maintenance is the best and
time-tested illustration (10). The effect of
metronomic therapy on tumor microen-
vironment like inhibition of angiogen-
esis and immune modulation may be
best utilized in maintenance setting when
the disease burden is low. The “multi-
targeted-metronomic-MTD chemo-switch
(C-S)” model is the proof of concept for
this strategy (31). It consists of admin-
istration of MTD chemotherapy followed
by multi-targeted anti-angiogenic main-
tenance therapy. Recently, Vives et al.
have also demonstrated that in pancre-
atic tumor models, C-S schedule of MTD
and metronomic gemcitabine had the most
favorable effect. They also showed that in
contrast with standard doses of chemother-
apy, metronomic and C-S gemcitabine
both affect the pancreatic cancer stem cell
(CSC) population (32). Similarly, a study of
glioma subcutaneous xenograft model has
shown the sensitivity of CSC population
to metronomic cyclophosphamide admin-
istration (33). It has been proposed that
CSCs can play a role in the resistance to
conventional chemotherapy and radiother-
apy, therefore targeting CSCs or the stem
cell niche through antiangiogenesis with
C-S metronomic approach opens a new
avenue for clinical and preclinical research.
In a recent review on maintenance ther-
apy in NSCLC, Gerber et al. have suggested
metronomic maintenance as a biologically
rational approach (9).
CLINICAL EXPERIENCE OF
METRONOMICS AS MAINTENANCE
Although promising, metronomics as
maintenance has not been extensively
tested in clinical setting. Table 1 sum-
marizes the clinical studies exploring role
of metronomic therapies as maintenance.
Most of these studies are small and single
arm observations. However, a good safety
profile and promising efficacy has been
demonstrated by most of these studies.
The results of a phase 3 trial (CAIRO-
3) were presented at annual meeting of
ASCO in 2013. After randomization of
558 patients and median follow-up of
33 months, improvement in PFS and OS
was demonstrated with the use of main-
tenance metronomic dose of capecitabine
along with bevacizumab (34).
There are several ongoing clinical trials
which are evaluating the role of metro-
nomic maintenance in various combi-
nations in colorectal cancer, breast can-
cer, and ovarian cancer (Table 1). The
results of these trials will further clar-
ify the utility of metronomic therapies as
maintenance.
Three important aspects make metro-
nomics appealing for maintenance: (1)
favorable toxicity profile for long-term use.
(2) The selection of low cost drugs for
such regimens makes them widely practi-
cable globally, especially in low and mid-
dle income countries (LMICs). (3) Their
efficacy to target angiogenesis, CSCs, and
immune modulation make them capable of
overcoming resistance and delaying tumor
progression.
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POTENTIAL COMBINATION WITH
TARGETED THERAPIES
Combining MC with specific targeted ther-
apies may eventually enhance the efficacy
and specificity of a maintenance as demon-
strated in several preclinical models and
in the clinic (41–43). Noteworthy, the suc-
cess of combination of targeted therapies
with MTD chemotherapy has been vari-
able and showed mostly failure when it
was combined with anti-angiogenic TKIs
in contrast to monoclonal antibodies (44–
47). On the other hand, several preclinical
and early clinical studies have shown that
MC could be successfully combined with
Pazopanib, an oral multi-kinase inhibitor
showing encouraging activity in gyne-
cological cancer (48) and pediatric solid
tumors (41). MC, in that case, can be
used to bridge the gap between biologicals
and cytotoxics (48). The potential benefit
of long-term use of targeted angiogenic
inhibitors and MC can be gainfully utilized
in maintenance.
Repositioning of several other drugs like
celecoxib (49, 50), metformin (51, 52), pro-
pranolol (53, 54), valproic acid (55), ator-
vastatin (56), and itraconazole (57) which
have shown anticancer properties in several
preclinical, epidemiological, and clinical
settings, can also be considered along with
metronomic regimens for long-term use.
GLOBAL ONCOLOGY PERSPECTIVE
Ever-increasing cost of cancer treatment is
a great public and political concern even
in the developed world. In LMICs, where
most of the new cancer cases and cancer
deaths occur, access to most of modern
treatment modalities is beyond imagina-
tion. High income countries’ standards of
care, although appealing, are out of reach
for LMICs because of their cost, toxici-
ties, and the complex infrastructure and
technology needed. As we have proposed
earlier, metronomics may be a promising
alternative strategy for the improvement
of cancer care in LMICs (58). This treat-
ment strategy seems even more promis-
ing in maintenance setting where long-
term administration is required and can
be more acceptable because of favorable
toxicity profile and affordable cost.
CONCLUSION
The field of metronomics still is terra incog-
nita even after more than a decade since
conception. The selection of best metro-
nomic regimen for individual disease, the
ideal combination and scheduling, predic-
tive bio-markers, and the timing of insti-
tution are certain areas which still remain
unanswered. Apart from relapse/refractory
settings where this therapy has been tested
mostly and showed meaningful activity,
there is enough scientific rationale for their
evaluation as maintenance strategy. Pre-
clinical work for selection of drugs to
be used, identification of predictive bio-
markers, and rationale combination with
other biological agents are some areas
which warrant further research.
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